看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。! \: v+ S; U9 a9 A( N1 `
6 E7 t! b/ p0 s4 |, m" p" J+ s* d; Q0 g! C
Currently available feasibility data for possible combination strategies.
9 c' P( c+ D: Q& A————————————————————————————————
4 X" [6 ]) g% D3 G$ P) w* RCombination Feasibility according to preliminary data 7 U9 G* w1 |5 }. O- i
——————————————————————————————————7 W% X3 }! t3 l9 X- c7 O; I
Bevacizumab + sorafenib Yes, reduced dose
6 g4 ~( J# L% y6 @ p" TBevacizumab + sunitinib† No * @( q3 @1 ^5 p5 B
Bevacizumab + temsirolimus Yes " O6 S. _8 x4 W) l- c, ?, f
Bevacizumab + everolimus Yes ! Q: |: `: F( L5 B3 v
Sorafenib + sunitinib ? 5 [) c; @0 L; U/ S, c/ l( T; H5 s
Sorafenib + temsirolimus Yes, reduced dose 0 I4 C4 [- ^3 m0 y4 ^: V
Sorafenib + everolimus Yes, reduced dose . z+ Q+ O: ^% a1 m) k; t1 n
Sunitinib + temsirolimus† No
% }& R* _/ ]2 o/ _Sunitinib + everolimus ? 0 ]+ x8 }8 X. J+ P* u
Temsirolimus + everolimus ?
# c. X8 x. w* S3 ^' ]————————————————————7 N, X9 D1 u! _/ ?& b" \
†Led to US FDA warning.9 A0 @' l$ h8 t4 Y2 O+ r; ^/ a
?: As yet unattempted combination.1 B% y$ {% V8 e
|
显身卡
